Nothing Special   »   [go: up one dir, main page]

WO2005019435A3 - Anti-cancer vaccines - Google Patents

Anti-cancer vaccines Download PDF

Info

Publication number
WO2005019435A3
WO2005019435A3 PCT/US2004/027790 US2004027790W WO2005019435A3 WO 2005019435 A3 WO2005019435 A3 WO 2005019435A3 US 2004027790 W US2004027790 W US 2004027790W WO 2005019435 A3 WO2005019435 A3 WO 2005019435A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
cancer vaccines
restricted antigens
hla
vaccines
Prior art date
Application number
PCT/US2004/027790
Other languages
French (fr)
Other versions
WO2005019435A8 (en
WO2005019435A2 (en
Inventor
A John Barrett
Jeffrey Molldrem
Original Assignee
Univ Texas
Us Gov Health & Human Serv
Jeffrey Molldrem
A John Barrett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Us Gov Health & Human Serv, Jeffrey Molldrem, A John Barrett filed Critical Univ Texas
Priority to JP2006524856A priority Critical patent/JP2007504149A/en
Priority to AU2004267506A priority patent/AU2004267506A1/en
Priority to EP04782297A priority patent/EP1660636A4/en
Priority to CA002536654A priority patent/CA2536654A1/en
Publication of WO2005019435A2 publication Critical patent/WO2005019435A2/en
Publication of WO2005019435A8 publication Critical patent/WO2005019435A8/en
Publication of WO2005019435A3 publication Critical patent/WO2005019435A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464458—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present provides tumor-associated HLA-restricted antigens, and in particular HLA-­A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of the target protein cells.
PCT/US2004/027790 2003-08-26 2004-08-26 Anti-cancer vaccines WO2005019435A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006524856A JP2007504149A (en) 2003-08-26 2004-08-26 Anti-cancer vaccine
AU2004267506A AU2004267506A1 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines
EP04782297A EP1660636A4 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines
CA002536654A CA2536654A1 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49823803P 2003-08-26 2003-08-26
US60/498,238 2003-08-26

Publications (3)

Publication Number Publication Date
WO2005019435A2 WO2005019435A2 (en) 2005-03-03
WO2005019435A8 WO2005019435A8 (en) 2006-04-27
WO2005019435A3 true WO2005019435A3 (en) 2006-06-29

Family

ID=34216164

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/027790 WO2005019435A2 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines
PCT/US2004/027792 WO2005035714A2 (en) 2003-08-26 2004-08-26 Vaccines for cancer, autoimmune disease and infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2004/027792 WO2005035714A2 (en) 2003-08-26 2004-08-26 Vaccines for cancer, autoimmune disease and infections

Country Status (5)

Country Link
EP (2) EP1660636A4 (en)
JP (1) JP2007504149A (en)
AU (1) AU2004267506A1 (en)
CA (1) CA2536654A1 (en)
WO (2) WO2005019435A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101205064B1 (en) * 2005-04-26 2012-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 Compositions and methods for cancer immunotherapy
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
JP5731198B2 (en) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Use of liposomes in carriers containing a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20110097312A1 (en) * 2008-02-15 2011-04-28 Board Of Regents, The University Of Texas System Anti-cancer vaccines
WO2009146523A1 (en) 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
ES2855474T3 (en) 2011-10-06 2021-09-23 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases TLR2 activity and uses thereof
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
WO2014066243A1 (en) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
RU2014102941A (en) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Vaccine composition for administration through the mucous membrane
CN103961306A (en) * 2013-02-05 2014-08-06 日东电工株式会社 Vaccine composition for transdermal administration
GB201519303D0 (en) 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266694C1 (en) * 2000-06-02 2005-09-01 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLLDREM ET AL: "Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units.", BLOOD., vol. 90, no. 7, October 1997 (1997-10-01), pages 2529 - 2534, XP002300135 *
VAN DER GELD ET AL: "In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG).", CLIN EXP IMMUNOL., vol. 122, December 2000 (2000-12-01), pages 504 - 513, XP008072447 *

Also Published As

Publication number Publication date
CA2536654A1 (en) 2005-03-03
WO2005019435A8 (en) 2006-04-27
WO2005035714A3 (en) 2009-04-16
WO2005035714A2 (en) 2005-04-21
JP2007504149A (en) 2007-03-01
AU2004267506A1 (en) 2005-03-03
EP1670899A2 (en) 2006-06-21
WO2005019435A2 (en) 2005-03-03
EP1660636A4 (en) 2009-07-01
EP1660636A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
WO2005019435A8 (en) Anti-cancer vaccines
WO2007067682A3 (en) In vivo cell surface engineering
EP2172476A3 (en) Compositions and methods for WT1 specific immunotherapy
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
WO2002014503A3 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
WO2000018795A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2004067023A3 (en) Survivin-derived peptides and use thereof
WO2008070042A3 (en) High potency recombinant antibodies, methods for producing them and use in cancer therapy
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2005123908A3 (en) Novel cancer cell lines and uses thereof
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001061017A3 (en) Modified cytokines for use in cancer therapy
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2536654

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006524856

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004782297

Country of ref document: EP

Ref document number: 2004267506

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004267506

Country of ref document: AU

Date of ref document: 20040826

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004267506

Country of ref document: AU

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 09/2005 UNDER (72, 75) REPLACE "BARRETT, JOHN, A." BY "BARRETT, A. JOHN"

WWP Wipo information: published in national office

Ref document number: 2004782297

Country of ref document: EP